![[e-mail]](http://wwwcache.wral.com/presentation/v2/images/header/email-15x10.gif){kind=small}
Subscribe
![[e-mail]](http://wwwcache.wral.com/presentation/v1/images/icon_email-story.gif){kind=icon}
Get News Alerts to your Email & Cell Phone
DURHAM, NC — The first full year of a selling partnership with Allergan produced substantial revenue growth for
Inspire Pharmaceuticals
(Nasdaq: ISPH).
Inspire reported 2005 revenues of $23.3 million, up from $11 million in 2004. Primary reasons are the partnership with Allergan for the eye drop drug Elestat ($16.8 million) and artificial tear drug Restasis ($6.5 million).
Helped by a $4.3 million reduction in research and development costs in the fourth quarter, Inspire cut its losses for 2005 to $7.1 million, or 17 cents. Losses the previous year were $11.8 million.
![[SLIDESHOW]](http://wwwcache.wral.com/asset/share/2012/02/09/10711513/4f348e7981bb5-51x75.jpg)
![[SLIDESHOW]](http://wwwcache.wral.com/asset/news/local/2012/02/11/10717396/thumbnail-100x75.jpg)
![[SLIDESHOW]](http://wwwcache.wral.com/asset/entertainment/out_and_about/2012/02/04/10712136/pics_agunn53833-100x75.jpg)
![[SLIDESHOW]](http://wwwcache.highschoolot.com/asset/content/2012/02/11/10717011/10717011-1328936455-100x75.jpg)
![[SLIDESHOW]](http://wwwcache.highschoolot.com/asset/content/2012/02/11/10717059/10717059-1328939591-100x75.jpg)
![[SLIDESHOW]](http://wwwcache.highschoolot.com/asset/content/2012/02/11/10717043/10717043-1328939633-100x75.jpg)
WRAL.com welcomes your comments on this story. All comments are moderated prior to publication based on our posting guidelines. Please review them prior to posting and if your message is not approved.
This story is closed for comments. Comments on WRAL.com news stories are accepted and moderated between the hours of 8 a.m. and 8 p.m. Monday through Friday.